April 22, 2024
Alecensa (alectinib), an oral ALK inhibitor originated by Chugai Pharmaceutical, was approved in the US as the first post-surgery adjuvant treatment for patients with ALK-positive early-stage non-small cell lung cancer (NSCLC). The Roche group company said on April 19 that...read more